A Republican bill with 6 Democratic cosponsors · See all 9 cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "Priority for Pediatric Cures Act," seeks to amend the Federal Food, Drug, and Cosmetic Act. The primary goal is to permanently extend the authority granted to the Secretary of Health and Human Services. This authority involves awarding priority review vouchers for rare pediatric disease products.
Yes· 3 of 5
- Scored +7
Would children be better off under this?
The bill specifically targets rare pediatric diseases, which directly benefits children.
- Scored +5
Does this make health care easier to get in general?
The bill incentivizes the development of treatments for rare pediatric diseases.
- Scored +5
Does this put more money into medical research?
By extending vouchers, it incentivizes research into rare pediatric disease products.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
- Permanent Authority for Rare Disease Vouchers: The bill proposes to strike paragraph (5) of Section 529(b) of the Federal Food, Drug, and Cosmetic Act, which serves to permanently extend the Secretary of Health and Human Services' authority to award priority review vouchers for rare pediatric disease products (Section 2).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would children be better off under this? — The bill specifically targets rare pediatric diseases, which directly benefits children. Would business owners be better off under this? — Pharmaceutical companies benefit from the incentive of priority review vouchers.
- Healthcare
- Does this make health care easier to get in general? — The bill incentivizes the development of treatments for rare pediatric diseases. Does this put more money into medical research? — By extending vouchers, it incentivizes research into rare pediatric disease products.
- Education And Technology
- Does this put more money into scientific research? — The bill provides a mechanism to incentivize research into rare diseases via priority review vouchers.
- 10/26/2026
- 2 Cosponsors added.
- 10/19/2026
- 1 Cosponsor added.
- 10/1/2026
- 1 Cosponsor added.
- 9/14/2026
- Referred to the House Committee on Energy and Commerce.
- 5 Cosponsors added.
- Introduced in House
Jake AuchinclossDemocrat · Massachusetts
Nanette BarragánDemocrat · California
Kat CammackRepublican · Florida
Thomas KeanRepublican · New Jersey
Michael McCaulRepublican · Texas
Kevin MullinDemocrat · California
Josh RileyDemocrat · New York
Shri ThanedarDemocrat · Michigan
Eugene VindmanDemocrat · Virginia